International Journal of Medical Science and Pharmaceutical Research

Lipoprotein(a) [Lp(a)] is a lipoprotein particle predominantly determined by genetic factors and independently associated with atherosclerotic cardiovascular disease and calcific aortic valve stenosis. Although its recognition as a risk modifier has increased, few widely available interventions substantially lower its concentrations. Statins and ezetimibe do not meaningfully reduce Lp(a), whereas PCSK9 inhibitors produce moderate reductions, and therapies directed at apolipoprotein(a) remain under development or cardiovascular outcome evaluation. In this setting, nutraceuticals have been proposed as accessible alternatives or adjuncts. This practical review summarizes the available clinical evidence for L-carnitine, coenzyme Q10, flaxseed, curcumin, berberine, pectin, Ginkgo biloba, Xuezhikang, N-acetylcysteine, phytosterols, omega-3 fatty acids, and other natural products. The most consistent evidence for Lp(a) lowering comes from meta-analyses of randomized trials of L-carnitine, coenzyme Q10, and flaxseed, although absolute effects are generally modest. Pectin, Ginkgo biloba, and Xuezhikang produced larger reductions in individual studies, but with low certainty and limited replication. No evidence demonstrates that nutraceutical-mediated Lp(a) lowering reduces cardiovascular events. We propose a pragmatic approach centered on global cardiovascular risk stratification, intensive control of LDL-C and other modifiable risk factors, and, only after shared decision-making, an individualized trial of one nutraceutical followed by laboratory reassessment after 8-12 weeks. Nutraceuticals should neither replace proven therapies nor be used as an isolated strategy in individuals at high or very high risk.

lipoprotein(a), Lp(a), nutraceuticals, L-carnitine, coenzyme Q10, cardiovascular risk, cardiovascular prevention.

1. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct 14;43(39):3925-3946. doi: 10.1093/eurheartj/ehac361. PMID: 36036785; PMCID: PMC9639807.
2. Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):e48-e60. doi: 10.1161/ATV.0000000000000147. Epub 2021 Oct 14. PMID: 34647487; PMCID: PMC9989949.
3. Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017 Feb 14;69(6):692-711. doi: 10.1016/j.jacc.2016.11.042. PMID: 28183512.
4. Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020 Jun 21;41(24):2275-2284. doi: 10.1093/eurheartj/ehz310. PMID: 31111151.
5. de Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, et al. Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022 May 5;29(5):779-792. doi: 10.1093/eurjpc/zwab171. PMID: 34849724.
6. Awad K, Mikhailidis DP, Katsiki N, Muntner P, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group. Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Drugs. 2018 Mar;78(4):453-462. doi: 10.1007/s40265-018-0870-1. PMID: 29396832.
7. Sahebkar A, Simental-Mendía LE, Pirro M, Banach M, Watts GF, Sirtori C, et al. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2018 Dec 14;8(1):17887. doi: 10.1038/s41598-018-36204-7. Erratum in: Sci Rep. 2020 Feb 14;10(1):2999. doi: 10.1038/s41598-020-59903-6. PMID: 30552391; PMCID: PMC6294784.
8. Baragetti A, Da Dalt L, Norata GD. New insights into the therapeutic options to lower lipoprotein(a). Eur J Clin Invest. 2024 Sep;54(9):e14254. doi: 10.1111/eci.14254. Epub 2024 May 22. PMID: 38778431.9. 
9. HPS2-THRIVE Collaborative Group; Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014 Jul 17;371(3):203-12. doi: 10.1056/NEJMoa1300955. PMID: 25014686.
10. Mackinnon LT, Hubinger L, Lepre F. Effects of physical activity and diet on lipoprotein(a). Med Sci Sports Exerc. 1997 Nov;29(11):1429-36. doi: 10.1097/00005768-199711000-00007. PMID: 9372478.
11. Enkhmaa B, Berglund L. Non-genetic influences on lipoprotein(a) concentrations. Atherosclerosis. 2022 May;349:53-62. doi: 10.1016/j.atherosclerosis.2022.04.006. PMID: 35606076; PMCID: PMC9549811.
12. Jamialahmadi T, Reiner Ž, Alidadi M, Kroh M, Almahmeed W, Ruscica M, et al. The Effect of Bariatric Surgery on Circulating Levels of Lipoprotein (a): A Meta-analysis. Biomed Res Int. 2022 Aug 17;2022:8435133. doi: 10.1155/2022/8435133. PMID: 36033567; PMCID: PMC9402303.
13. Sosnowska B, Stepinska J, Mitkowski P, Bielecka-Dabrowa A, Bobrowska B, Budzianowski J, et al. Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels. Arch Med Sci. 2024 Jan 31;20(1):8-27. doi: 10.5114/aoms/183522. PMID: 38414479; PMCID: PMC10895977.
14. Connolly CM, Li J, Goldman D, Fava A, Magder L, Petri M. Lipoprotein(a) in systemic lupus erythematosus is associated with history of proteinuria and reduced renal function. Lupus. 2022 Oct;31(11):1367-1372. doi: 10.1177/09612033221111958. Epub 2022 Jul 1. PMID: 35775881; PMCID: PMC9547824.
15. Barbagallo CM, Cefalù AB, Giammanco A, Noto D, Caldarella R, Ciaccio M, et al. Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation. Life (Basel). 2021 Apr 5;11(4):315. doi: 10.3390/life11040315. PMID: 33916487; PMCID: PMC8067409.
16. Serban MC, Sahebkar A, Mikhailidis DP, Toth PP, Jones SR, Muntner P, et al. Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2016 Jan 12;6:19188. doi: 10.1038/srep19188. PMID: 26754058; PMCID: PMC4709689.
17. Sahebkar A, Simental-Mendía LE, Stefanutti C, Pirro M. Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis. Pharmacol Res. 2016 Mar;105:198-209. doi: 10.1016/j.phrs.2016.01.030. Epub 2016 Feb 2. PMID: 26836888.
18. Hadi A, Askarpour M, Ziaei R, Venkatakrishnan K, Ghaedi E, Ghavami A. Impact of flaxseed supplementation on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2020 Jul;34(7):1599-1608. doi: 10.1002/ptr.6640. Epub 2020 Feb 19. PMID: 32073724.
19. Sahebkar A, Katsiki N, Ward N, Reiner Ž. Flaxseed Supplementation Reduces Plasma Lipoprotein(a) Levels: A Meta-Analysis. Altern Ther Health Med. 2021 May;27(3):50-53. PMID: 31634874.
20. Fogacci F, Avagimyan A, Cesaro A, Bernardi M, Perone F, Giovannini M, et al. The effect of highly bioavailable forms of curcumin on lipoprotein(a) plasma levels: A systematic review and meta-analysis of randomized clinical studies. Prostaglandins Other Lipid Mediat. 2025 Jun;178:106994. doi: 10.1016/j.prostaglandins.2025.106994. Epub 2025 Apr 17. PMID: 40252824.
21. Zhao JV, Chen B, Chan YH, Zhang J, Xia Y, Blais JE, et al. Sex-Specific Lipid, Apolipoprotein B, and Lipoprotein(a) Responses to Berberine Based on 2 Randomized Placebo-Controlled Trials. JACC Asia. 2026 Jul 11:S2772-3747(26)00440-0. doi: 10.1016/j.jacasi.2026.06.011. Epub ahead of print. PMID: 42470424. 
22. Momtazi-Borojeni AA, Katsiki N, Pirro M, Banach M, Rasadi KA, Sahebkar A. Dietary natural products as emerging lipoprotein(a)-lowering agents. J Cell Physiol. 2019 Aug;234(8):12581-12594. doi: 10.1002/jcp.28134. Epub 2019 Jan 13. PMID: 30637725; PMCID: PMC13484089.
23. Kroon AA, Demacker PN, Stalenhoef AF. N-acetylcysteine and serum concentrations of lipoprotein(a). J Intern Med. 1991 Dec;230(6):519-26. doi: 10.1111/j.1365-2796.1991.tb00483.x. PMID: 1836221.
24. Rouhi H, Ganji F. Effects of N-acetyl cysteine on serum lipoprotein (a) and proteinuria in type 2 diabetic patients. J Nephropathol. 2013 Jan;2(1):61-6. doi: 10.5812/nephropathol.8940. Epub 2013 Jan 1. PMID: 24475426; PMCID: PMC3886171.
25. Simental-Mendía LE, Aguillón-Marín P, Sahebkar A. Effect of omega-3 supplementation on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized controlled trials. PharmaNutrition. 2026;35:100468. doi:10.1016/j.phanu.2025.100468.
26. O'Donoghue ML, Rosenson RS, Gencer B, López JAG, Lepor NE, Baum SJ, et al; OCEAN(a)-DOSE Trial Investigators. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022 Nov 17;387(20):1855-1864. doi: 10.1056/NEJMoa2211023. Epub 2022 Nov 6. PMID: 36342163.
27. Nissen SE, Wang Q, Nicholls SJ, Navar AM, Ray KK, Schwartz GG, et al. Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial. JAMA. 2024 Dec 17;332(23):1992-2002. doi: 10.1001/jama.2024.21957. PMID: 39556769; PMCID: PMC11574722..
28. Nicholls SJ, Ni W, Rhodes GM, Nissen SE, Navar AM, Michael LF, et al. Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial. JAMA. 2025 Jan 21;333(3):222-231. doi: 10.1001/jama.2024.24017. PMID: 39556768; PMCID: PMC11574718.
29. Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, et al. Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial. JAMA. 2023 Dec 5;330(21):2075-2083. doi: 10.1001/jama.2023.21835. PMID: 37952254; PMCID: PMC10641766.